HUMAN HSP40
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric(1) Consistent with protein copy count | Chain A; UniProt 1–76 | Fragment:J-DOMAIN | No other associated polymer | SOLUTION NMR NMR measurement conditions:pH 5.8;303 K | Resolution not provided |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 1HDJ | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2QLD human Hsp40 Hdj1 Deposited 2007-07-12 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
158–340(183 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;295 K;100mM Citric buffer, PEG400 25%, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.70 Å R-free 0.336 |
| 3AGX Crystal structure of human Hsp40 Hdj1 peptide-binding domain Deposited 2010-04-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
161–340(180 aa)
Fragment:UNP residues 161-340
Chain B
161–340(180 aa)
Fragment:UNP residues 161-340
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;293 K;13% PEG 3350, 0.1M Na citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.85 Å R-free 0.247 |
| 3AGY Crystal structure of human Hsp40 Hdj1 peptide-binding domain complexed with a C-terminal peptide of Hsp70 Deposited 2010-04-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 5 PDB declaration: pentameric |
Chain A
161–340(180 aa)
Fragment:UNP residues 161-340
Chain B
161–340(180 aa)
Fragment:UNP residues 161-340
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;277 K;18% PEG 3350, 0.1M Na citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.85 Å R-free 0.247 |
| 3AGZ Crystal structure of human Hsp40 Hdj1 peptide-binding domain complexed with a C-terminal peptide of Hsp70 Deposited 2010-04-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 6 PDB declaration: hexameric |
Chain A
151–340(190 aa)
Fragment:UNP residues 151-340
Chain B
151–340(190 aa)
Fragment:UNP residues 151-340
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.8;277 K;18% PEG 3350, 0.1M CHES, pH 8.8, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.51 Å R-free 0.269 |
| 4WB7 Crystal structure of a chimeric fusion of human DnaJ (Hsp40) and cAMP-dependent protein kinase A (catalytic alpha subunit) Deposited 2014-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
2–70(69 aa)
Fragment:UNP P25685 residues 2-70,UNP P17612 residues 16-351
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | ATP ADENOSINE-5'-TRIPHOSPHATE × 1 ZN ZINC ION × 9 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;295 K;70mM sodium cacodylate pH 6.5, 150mM magnesium acetate, 20mM zinc chloride, 5% glycerol, 11.5% PEG 8000
|
Resolution 1.90 Å R-free 0.188 |
| 4WB7 Crystal structure of a chimeric fusion of human DnaJ (Hsp40) and cAMP-dependent protein kinase A (catalytic alpha subunit) Deposited 2014-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
2–70(69 aa)
Fragment:UNP P25685 residues 2-70,UNP P17612 residues 16-351
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | ATP ADENOSINE-5'-TRIPHOSPHATE × 1 ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;295 K;70mM sodium cacodylate pH 6.5, 150mM magnesium acetate, 20mM zinc chloride, 5% glycerol, 11.5% PEG 8000
|
Resolution 1.90 Å R-free 0.188 |
| 6BYR Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PKAc alpha Deposited 2017-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–70(69 aa)
Chain C
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) | ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM NaCl, 16-18% pentaerythritol propoxylate and 10% dimethyl sulfoxide
|
Resolution 3.66 Å R-free 0.249 |
| 6BYR Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PKAc alpha Deposited 2017-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | ATP ADENOSINE-5'-TRIPHOSPHATE × 1 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM NaCl, 16-18% pentaerythritol propoxylate and 10% dimethyl sulfoxide
|
Resolution 3.66 Å R-free 0.249 |
| 6BYR Structures of the PKA RI alpha holoenzyme with the FLHCC driver J-PKAc alpha or native PKAc alpha Deposited 2017-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | ATP ADENOSINE-5'-TRIPHOSPHATE × 1 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM NaCl, 16-18% pentaerythritol propoxylate and 10% dimethyl sulfoxide
|
Resolution 3.66 Å R-free 0.249 |
| 6WJF PKA RIIbeta holoenzyme with DnaJB1-PKAc fusion in fibrolamellar hepatoceullar carcinoma Deposited 2020-04-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–70(69 aa)
Chain B
2–70(69 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 7.50 Å |
| 6WJG PKA RIIbeta holoenzyme with DnaJB1-PKAc fusion in fibrolamellar hepatoceullar carcinoma Deposited 2020-04-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–70(69 aa)
Chain B
2–70(69 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 6.20 Å |
| 6Z5N DnaJB1 JD-GF Deposited 2020-05-27 | Different construct Different experimental conditions | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
1–110(110 aa)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 50;Pressure 1
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 150;Pressure 1
NMR sample composition
4.0 mM [U-13C; U-15N] DnaJB1 JD-GF, 2.0 mM [U-15N] DnaJB1 JD-GF, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.4 mM [U-15N] DnaJB1 JD-GF, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
2.5 mM [U-13C; U-15N] DnaJB1 JD-GF, 100% D2O | 100% D2O
NMR sample composition
4.0 mM [U-13C; U-15N] DnaJB1 JD-GF, 2.0 mM [U-15N] DnaJB1 JD-GF, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 7NDX Crystal structure of the human HSP40 DNAJB1-CTDs in complex with a peptide of NudC Deposited 2021-02-02 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
157–340(184 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;298 K;0.1 M of sodium acetate trihydrate and 15% (v/v) of polyethylene glycol 400
|
Resolution 2.54 Å R-free 0.268 |
| 8FE2 Structure of J-PKAc chimera complexed with Aplithianine A Deposited 2022-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | XTI 6-[(6M)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-9H-purine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 20% PEG 3350
|
Resolution 2.34 Å R-free 0.251 |
| 8FE2 Structure of J-PKAc chimera complexed with Aplithianine A Deposited 2022-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | XTI 6-[(6M)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-9H-purine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 20% PEG 3350
|
Resolution 2.34 Å R-free 0.251 |
| 8FE5 Structure of J-PKAc chimera complexed with Aplithianine B Deposited 2022-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | XTT 6-[(6P)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7,9-dihydro-8H-purin-8-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium Sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.51 Å R-free 0.243 |
| 8FE5 Structure of J-PKAc chimera complexed with Aplithianine B Deposited 2022-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | XTT 6-[(6P)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7,9-dihydro-8H-purin-8-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium Sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.51 Å R-free 0.243 |
| 8FEC Structure of J-PKAc chimera complexed with Aplithianine derivative Deposited 2022-12-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | XU0 6-[(6P)-6-(4-bromo-1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7H-purine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.70 Å R-free 0.287 |
| 8FEC Structure of J-PKAc chimera complexed with Aplithianine derivative Deposited 2022-12-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | XU0 6-[(6P)-6-(4-bromo-1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7H-purine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.70 Å R-free 0.287 |
| 9NFS Structure of J-PKAc chimera in complex with Aplithianine j1 Deposited 2025-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | A1BX1 (4P)-4-[4-(pyrimidin-4-yl)-3,4-dihydro-2H-1,4-thiazin-6-yl]-1H-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;277.15 K;0.2 M LiCl, 0.1 M hopes, pH 7.6, 25% PEG 3350
|
Resolution 2.45 Å R-free 0.334 |
| 9NFS Structure of J-PKAc chimera in complex with Aplithianine j1 Deposited 2025-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
2–70(69 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | A1BX1 (4P)-4-[4-(pyrimidin-4-yl)-3,4-dihydro-2H-1,4-thiazin-6-yl]-1H-pyrrolo[2,3-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;277.15 K;0.2 M LiCl, 0.1 M hopes, pH 7.6, 25% PEG 3350
|
Resolution 2.45 Å R-free 0.334 |
14 other PDB entries and 21 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | DNJB1_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 1–76; UniProt 1–76 |